SS
VERV

SBI Securities’s Verve Therapeutics VERV Stock Holding History

SBI Securities’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-158
Closed -$1.77K – 4320
2025
Q2 		$1.77K Sell
158
-478
-75% -$2.73K ﹤0.01% 2438
2025
Q1 		$2.91K Buy
636
+100
+19% +$670 ﹤0.01% 2135
2024
Q4 		$3.02K Buy
+536
New +$3.02K ﹤0.01% 2120

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SBI Securities's VERV Position: Q3 2025 in Review

SBI Securities sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 158 shares — an estimated $1.77K sold.

SBI Securities first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $3.02K in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • SBI Securities reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 158 Verve Therapeutics shares in Q3 2025, an estimated $1.77K.
  • SBI Securities first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Verve Therapeutics position peaked at $3.02K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.